Discovery, stereospecific characterization and peripheral modification of 1-(pyrrolidin-1-ylmethyl)-2-[(6-chloro-3-oxo-indan)-formyl]-1,2,3,4-tetrahydroisoquinolines as novel selective κ opioid receptor agonists

Abstract

A novel series of 1-(pyrrolidin-1-ylmethyl)-2-[(3-oxo-indan)-formyl]-1,2,3,4-tetrahydroisoquinoline derivatives maj-3a–maj-3u were synthesized and evaluated in vitro for their binding affinity at κ-opioid receptors. Maj-3c displayed the highest affinity for κ-opioid receptors (K_i = 0.033 nM) among all the compounds evaluated. Furthermore, all four stereoisomers of compound 3c were prepared, and (1S,18S)-3c was identified as the most potent (K_i = 0.0059 nM) κ-opioid receptor agonist among the four stereoisomers. Maj-3c produced significant antinociception (ED₅₀ = 0.000406 mg kg⁻¹) compared to U-50,488H and original BRL 52580 in the acetic acid writhing assay, but its strong sedative effect (ED₅₀ = 0.000568 mg kg⁻¹) observed in the mouse rotation test reduced its druggability. To minimize the central nervous system side effects, a series of hydroxyl-containing analogs of maj-3c were synthesized, and maj-11a was found to be a potent κ-opioid receptor agonist (K_i = 35.13 nM). More importantly, the dose for the sedative effect (ED₅₀ = 9.29 mg kg⁻¹) of maj-11a was significantly higher than its analgesic dose (ED₅₀ = 0.392 mg kg⁻¹), which made it a promising peripheral analgesic candidate compound with weak sedative side effects.